Clinical trials · Baltimore, MD
Lung Cancer (NSCLC) clinical trials in Baltimore
We’re tracking 111 recruiting lung cancer (nsclc) studies with a site in or near Baltimore — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Baltimore
- NCT04077099RecruitingPhase 1/Phase 2
Study drug for lung cancer with MET changes
This trial tests REGN5093, a study drug, in adults with advanced lung cancer that has a specific change called a MET alteration. If you have this MET change, the study aims to see how well the drug controls the cancer and how safe it is.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06449313RecruitingPhase 2
Immunotherapy before lung cancer surgery for stage 3 disease
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help shrink stage 3 lung cancer and improve outcomes. The goal is to make the tumor easier to remove and possibly lower the chance of it coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07195695RecruitingPhase 3
Zongertinib after surgery for HER2-mutated lung cancer
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06545331RecruitingPhase 1
A study of XB010 for advanced solid tumors
This trial tests an investigational drug called XB010 for people with solid tumors that have spread or cannot be removed by surgery. It aims to see if XB010 is safe and effective for several cancer types, including lung, breast, head and neck, and esophageal cancers.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05715229RecruitingPhase 2
Blood test–guided treatment choice for advanced lung cancer
This Phase 2 study tests how results from blood cancer DNA tests (ctDNA) can help choose the best immune therapy approach for newly diagnosed, advanced lung cancer. It aims to improve outcomes by matching treatment decisions to a patient’s immune and blood test “profile.”
Washington D.C., District of ColumbiaAges 18 years+ - NCT06162221RecruitingPhase 1/Phase 2
Study of RAS inhibitors for advanced RAS-mutated lung cancer
This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06077760RecruitingPhase 3
Personalized cancer vaccine plus Keytruda for lung cancer after surgery
This study tests a new personalized cancer vaccine (V940) plus Keytruda versus a placebo plus Keytruda for people with non-small cell lung cancer that was removed by surgery. The goal is to see if the vaccine helps prevent the cancer from coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07288177RecruitingPhase 2
A study of Rina-S for people with non-small cell lung cancer
This trial tests a new drug called Rina-S for people with non-small cell lung cancer that has spread or can't be removed by surgery. It aims to see if the drug can shrink tumors and how safe it is.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06922591RecruitingPhase 1/Phase 2
TNG462 for pancreatic and lung cancer with MTAP loss
This trial tests a new drug called TNG462, alone or combined with other drugs, for people with advanced pancreatic or non-small cell lung cancer whose tumors have a specific genetic change (loss of MTAP and a RAS mutation). It aims to see if TNG462 is safe and works better than current treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07154706RecruitingPhase 3
Taletrectinib vs placebo after surgery for ROS1-positive lung cancer
This trial tests whether taletrectinib (a targeted pill) can help prevent lung cancer from coming back after surgery in people whose tumors have a ROS1 gene change. You would take either taletrectinib or a placebo (inactive pill) for about a year after surgery.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07566052RecruitingPhase 3
Comparing a new KRAS drug to docetaxel for advanced lung cancer
This trial tests a new pill (setidegrasib) against a standard chemo drug (docetaxel) for people with a specific type of advanced lung cancer that has a KRAS G12D mutation. The goal is to see which treatment works better.
Arlington, VirginiaAges 18 years+ - NCT06712316RecruitingPhase 2/Phase 3
Testing a new drug combo for advanced lung cancer
This trial tests a new drug called BNT327 combined with chemotherapy and other treatments for people with advanced non-small cell lung cancer (NSCLC) who have not had any prior treatment. The goal is to see if this combination is safe and works better than current options.
Arlington, VirginiaAges 18 years+ - NCT07327489Recruiting
Live tumor biopsy study to predict immunotherapy response
This trial studies how well immunotherapy might work by analyzing fresh tumor biopsies. It may help predict which treatments are best for your cancer.
Frederick, MarylandAges 18 years+
Hear when a new Lung Cancer (NSCLC) trial opens near Baltimore, MD
We’ll email you when one opens near Baltimore, MD — at most once a week, no account needed, unsubscribe anytime.
Lung Cancer (NSCLC) trials in other cities
Where these studies are running near Baltimore
Institutions with a site for the recruiting lung cancer (nsclc) studies listed above.
- Georgetown University Medical Center · 8 studies
- George Washington University Hospital · 2 studies
- Virginia Cancer Specialists · 2 studies
- Frederick Health Hospital
- James M Stockman Cancer Institute
- Johns Hopkins Medicine
- MedStar Georgetown University Hospital
What taking part in a lung cancer (nsclc) study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting lung cancer (nsclc) studies in Maryland.
Common questions
- Are there lung cancer (nsclc) clinical trials near Baltimore?
- Yes. We're currently tracking 111 recruiting lung cancer (nsclc) studies with a site near Baltimore, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung cancer (nsclc) study near Baltimore?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Baltimore to take part?
- Not necessarily. These studies have a site near Baltimore, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung cancer (nsclc) trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung cancer (nsclc) studies open near Baltimore regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.